Fenilin (phenindione) tablets 0.03 №20

$8.00

Manufacturer: Ukraine

Prevention and treatment of thrombosis (especially deep veins of the lower extremities), thromboembolic complications (pulmonary embolism, embolic strokes, myocardial infarction) and thrombosis in the postoperative period, in patients with mechanical prosthetic heart valves.

Category:

Description

Fenilin Storage
active substance: phenindione;

1 tablet contains phenylin (phenynedione) 30 mg;

excipients: lactose monohydrate; potato starch; talc; citric acid, monohydrate.

Fenilin Dosage form
Tablets.

Basic physical and chemical properties: tablets of white or white with a creamy shade of color, flat-cylindrical form with a facet. Impregnations are allowed.

Fenilin Pharmacotherapeutic group
Antithrombotic drugs. Vitamin K antagonists. ATX code B01A A02.

Pharmacological properties
Pharmacodynamics. An agent that affects blood clotting and platelet function. Indirect anticoagulant.

The mechanism of action is due to competitive antagonism with vitamin K. Fenindione blocks vitamin K-reductase, disrupts the formation in the liver of the active form of vitamin K, necessary for the synthesis of prothrombin and other coagulation factors (VII, IX and X). Causes hypoprothrombinemia.

Reduces plasma tolerance to heparin, blood lipids and improves vascular permeability.

The hypocoagulant effect (decrease in the concentration of coagulation factors) develops gradually (due to the action of previously synthesized coagulation factors), is manifested in 8-10 hours and reaches a maximum in 24-36 hours after ingestion. Duration of action – 1-4 days after drug withdrawal.

Pharmacokinetics.

After oral administration it is quickly and almost completely absorbed. Protein binding is not strong. Passes through histohematological barriers (including placental), accumulates in tissues. Metabolized in the liver by cytochrome P450. Excreted by the kidneys unchanged and as metabolites. It can accumulate.

Indication
Prevention and treatment of thrombosis (especially deep veins of the lower extremities), thromboembolic complications (pulmonary embolism, embolic strokes, myocardial infarction) and thrombosis in the postoperative period, in patients with mechanical prosthetic heart valves.

Contraindication
Hypersensitivity to the components of the drug; hemophilia; threat of abortion; large postoperative wounds; bleeding from the digestive, respiratory, genitourinary system; recently undergone surgery or trauma to the brain / spinal cord, eyes; recent lumbar anesthesia, liver or kidney biopsy; severe hepatic and / or renal failure; hemorrhagic diathesis; hypocoagulation (initial prothrombin level less than 70%); erosive-ulcerative lesions of the digestive tract; severe hypertension; a condition in which therapy cannot be performed safely enough (eg psychosis, dementia, alcoholism).

Interaction with other medicinal products and other forms of interaction
The effect of the drug is enhanced by thrombolytic, antiplatelet agents, anticoagulants, adrenocorticotropic hormone, anabolics, azathioprine, allopurinol, amiodarone, anesthetics, narcotic analgesics, androgens, antibiotics, tricyclic antidepressants, antidepressants, drugs clofibrate, metronidazole, paracetamol, reserpine, vitamin E, butadione, sulfonamides, disulfiram, quinidine, cyclophosphamide, thyroid hormones, iodine, liquid paraffin, cimetidine, and other microsomal oxidation inhibitors. The effect of the drug is weakened by vitamin K, propranolol, urine alkalizing agents, antacids, cholestyramine, phenazone, haloperidol, diuretics, carbamazepine, barbiturates, oral contraceptives, rifampicin.